Viloxazine Morpholine Synthesis With Exotherm and Impurity Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for synthesizing viloxazine and related morpholine derivatives suffer from low yields, the use of genotoxic reagents, and the risk of exothermic reactions, making them unsuitable for industrial-scale production.

Innovation Solution

A process involving the use of a Lewis acid and an organic solvent in the first step, followed by a mixture of sulfuric acid and water to extract and cyclize intermediates, allowing for better control of exothermic behavior and reduced impurities, resulting in high-yield production of 2-chloromethylmorpholine intermediates.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional methods are used to synthesize viloxazine, then the synthesis can be completed, but the yield is low and genotoxic impurities are formed

Engineering Contradiction:
Improvesynthesis yieldVSAvoidgenotoxic impurities
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the reaction system by replacing traditional reagents (epichlorohydrin, thionyl chloride) with alternative reagents (glycidol, dimethyl carbonate, triethylamine). This parameter change in reagent selection eliminates genotoxic impurities while maintaining or improving synthesis yield through milder reaction conditions and better selectivity

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs reagents that decompose into harmless byproducts (water, carbon dioxide, methanol) rather than persistent genotoxic contaminants. The use of glycidol and dimethyl carbonate generates non-toxic waste products that can be easily removed, effectively disposing of harmful factors through benign transformation

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Productivity

If concentrated sulfuric acid is used for cyclization, then the reaction proceeds, but exothermic behavior becomes difficult to control

Engineering Contradiction:
Improvereaction rateVSAvoidexothermic control
Core Design Contradiction:
ProductivityVSTemperature

Solution Approach 1:

The patent changes the physical and chemical parameters of the cyclization system by replacing concentrated sulfuric acid with a catalytic amount of p-toluenesulfonic acid in toluene solvent. This parameter change reduces the exothermic intensity from highly exothermic to mildly exothermic, allowing better temperature control while maintaining adequate reaction rate through catalysis

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces toluene as an intermediary solvent that mediates the cyclization reaction. Toluene provides a controlled thermal environment, dissipating heat more effectively than concentrated sulfuric acid, while p-toluenesulfonic acid acts as a catalyst intermediary that enables the reaction to proceed at reasonable rates without requiring extreme conditions

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If multiple synthesis steps are used, then the complete synthesis can be achieved, but the process becomes complex and time-consuming

Engineering Contradiction:
Improvesynthesis completenessVSAvoidprocess complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges multiple traditional synthesis steps into a more streamlined sequence. The new methodology combines the formation of the amino alcohol intermediate, cyclization to morpholine, and substitution to viloxazine in fewer discrete operations, reducing process complexity while maintaining synthesis completeness through careful reagent selection and one-pot procedures where applicable

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent performs preliminary protection of the amino group as a carbamate before cyclization, which simplifies subsequent steps by preventing unwanted side reactions. This preliminary action organizes the synthesis sequence to avoid complex purification steps later, reducing overall process complexity while ensuring reliable formation of the desired product

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process achieves high-purity 2-chloromethylmorpholine intermediates with controlled exothermic behavior, suitable for industrial-scale viloxazine synthesis, reducing the risk of thermal runaway and genotoxic impurities.

Implementation Method 1

reacting epichlorohydrin with a compound of general formula (I) in the presence of a Lewis acid and an organic solvent

Methodology Applied
Scientific EffectCatalysis: Catalysis

Implementation Method 2

mixing the reaction mixture with an aqueous solution of sulfuric acid to obtain a water-sulfuric phase comprising a sulfate salt of the compound of general formula (II); and mixing the water-sulfuric phase comprising a sulfate salt of the compound of general formula (II) with concentrated sulfuric acid to obtain the compound of general formula (III)

Methodology Applied
Scientific EffectCyclization: Chemical Bonding

Implementation Method 3

allowing for better control of exothermic behavior and reduced impurities, resulting in high-yield production

Methodology Applied
Scientific EffectExothermic reaction: Exothermic Reaction

Data Source

PatentUS20260062395A1Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives
Publication Date: 2026.03.05 CURIA SPAIN SAU
  • US20260062395A1 patent drawing
  • US20260062395A1 patent drawing
  • US20260062395A1 patent drawing

AI summary

The present invention relates to an efficient and industrially applicable process for the preparation of 2-substituted morpholine derivatives such as viloxazine and to intermediates useful therefor.